Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rafael Rosell

Showing results (211-220 of 470) with videos related to

Pageof 47
Sort By:
Translational Lung Cancer Research|July 23, 2021
A narrative review of the migration and invasion features of non-small cell lung cancer cells upon xenobiotic exposure: insights from <i>in vitro</i> studiesCatarina Albuquerque, Rita Manguinhas, João G Costa, et al.
The International Journal of Biological Markers|July 23, 2016
Low RAP80 mRNA expression correlates with shorter survival in sporadic high-grade serous ovarian carcinomaMargarita Romeo, Niki Karachaliou, Imane Chaid, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 26, 2011
Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patientsCarmen Balańa, Cristina Carrato, José Luis Ramírez, et al.
Antioxidants (Basel, Switzerland)|July 1, 2020
Impact of the APE1 Redox Function Inhibitor E3330 in Non-small Cell Lung Cancer Cells Exposed to Cisplatin: Increased Cytotoxicity and Impairment of Cell Migration and InvasionRita Manguinhas, Ana S Fernandes, João G Costa, et al.
Lung Cancer (Amsterdam, Netherlands)|June 17, 2008
Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancerMaría José Safont, Angel Artal-Cortes, Rafael Sirera, et al.
Pharmaceuticals (Basel, Switzerland)|March 26, 2022
Metformin Enhances TKI-Afatinib Cytotoxic Effect, Causing Downregulation of Glycolysis, Epithelial-Mesenchymal Transition, and EGFR-Signaling Pathway Activation in Lung Cancer CellsPedro Barrios-Bernal, Norma Hernandez-Pedro, Mario Orozco-Morales, et al.
Biochemical Pharmacology|July 14, 2024
Impact of the redox-active MnTnHex-2-PyP<sup>5+</sup> and cisplatin on the metabolome of non-small cell lung cancer cellsRita B Soares, Joana Pinto, Filipa Amaro, et al.
Seminars in Oncology|August 15, 2003
Targeted therapy in combination with gemcitabine in non-small cell lung cancerRafael Rosell, Lucio Crino, Kathleen Danenberg, et al.
Translational Lung Cancer Research|September 27, 2019
Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell linesJordi Codony-Servat, Santiago Viteri, Carles Codony-Servat, et al.
International Journal of Molecular Sciences|November 27, 2024
Prognostic Significance of PD-L1 Expression on Circulating Myeloid-Derived Suppressor Cells in NSCLC Patients Treated with Anti-PD-1/PD-L1 Checkpoint InhibitorsRoser Salvia, Laura G Rico, Teresa Morán, et al.
Pageof 47

Showing results (211-220 of 470) with videos related to

Sort By:
Pageof 47
Translational Lung Cancer Research|July 23, 2021
A narrative review of the migration and invasion features of non-small cell lung cancer cells upon xenobiotic exposure: insights from <i>in vitro</i> studiesCatarina Albuquerque, Rita Manguinhas, João G Costa, et al.
The International Journal of Biological Markers|July 23, 2016
Low RAP80 mRNA expression correlates with shorter survival in sporadic high-grade serous ovarian carcinomaMargarita Romeo, Niki Karachaliou, Imane Chaid, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 26, 2011
Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patientsCarmen Balańa, Cristina Carrato, José Luis Ramírez, et al.
Antioxidants (Basel, Switzerland)|July 1, 2020
Impact of the APE1 Redox Function Inhibitor E3330 in Non-small Cell Lung Cancer Cells Exposed to Cisplatin: Increased Cytotoxicity and Impairment of Cell Migration and InvasionRita Manguinhas, Ana S Fernandes, João G Costa, et al.
Lung Cancer (Amsterdam, Netherlands)|June 17, 2008
Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancerMaría José Safont, Angel Artal-Cortes, Rafael Sirera, et al.
Pharmaceuticals (Basel, Switzerland)|March 26, 2022
Metformin Enhances TKI-Afatinib Cytotoxic Effect, Causing Downregulation of Glycolysis, Epithelial-Mesenchymal Transition, and EGFR-Signaling Pathway Activation in Lung Cancer CellsPedro Barrios-Bernal, Norma Hernandez-Pedro, Mario Orozco-Morales, et al.
Biochemical Pharmacology|July 14, 2024
Impact of the redox-active MnTnHex-2-PyP<sup>5+</sup> and cisplatin on the metabolome of non-small cell lung cancer cellsRita B Soares, Joana Pinto, Filipa Amaro, et al.
Seminars in Oncology|August 15, 2003
Targeted therapy in combination with gemcitabine in non-small cell lung cancerRafael Rosell, Lucio Crino, Kathleen Danenberg, et al.
Translational Lung Cancer Research|September 27, 2019
Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell linesJordi Codony-Servat, Santiago Viteri, Carles Codony-Servat, et al.
International Journal of Molecular Sciences|November 27, 2024
Prognostic Significance of PD-L1 Expression on Circulating Myeloid-Derived Suppressor Cells in NSCLC Patients Treated with Anti-PD-1/PD-L1 Checkpoint InhibitorsRoser Salvia, Laura G Rico, Teresa Morán, et al.
Pageof 47